CA
NZ
UK
AU
IND
US
Bone Biologics (NASDAQ: BBLG) closed a private placement that generated roughly $3.0 million in gross proceeds, a cash infusion that stretches its operating runway through the second quarter of 2027 and funds the next phase of its NB1 spinal‑fusion program. The financing also attached …
A recent outbreak of Cyclospora presents immediate challenges to HHS Secretary Robert F. Kennedy Jr. as he attempts to reform the food system and rebuild trust in the CDC. The emergence of this foodborne illness resounds across the healthcare sector, particularly given the heightened …
Molina Healthcare, Inc. (NYSE: MOH) has unveiled second-quarter 2026 results, reporting an adjusted earnings per share (EPS) of $1.51, which outpaced analysts’ expectations of $1.40. The performance reflects ongoing adjustments within the Medicaid and Medicare segments, signaling a strategic positioning as the company navigates …
NewAmsterdam Pharma Co N.V. Is undergoing a significant leadership change as Chief Operating Officer Mr. Kling announces his resignation, effective August 14, 2026.
Serina Therapeutics, Inc. (NYSE American: SER) announced that Farrell Simon, Pharm.D. Has been appointed to its Board of Directors, with his service beginning in July 2026. Simon will serve on both the Audit Committee and the Compensation Committee, providing the board with additional depth …
Swedencare AB (publ) unveiled its second-quarter results for 2026, revealing a substantial miss in earnings expectations. The company posted earnings per share of $0.11 for the quarter, falling short of analyst estimates, which were set at $0.20. This disparity highlights ongoing challenges for the …
Tempest Therapeutics, Inc. (NASDAQ: TPST) has announced a significant collaboration agreement with Hebei Senlang Biotechnology Co. Ltd. to develop its proprietary TPST-4003 product candidate. This partnership marks a critical step for Tempest as it seeks to advance its innovative CAR-T cell therapy for treating …
Galderma, a prominent player in the aesthetic treatment industry, has observed a marked increase in demand for Botox, attributed to the effects of the so-called "Ozempic face" phenomenon. As the use of GLP-1 medications rises, which are known for weight loss but can lead …
Keros Therapeutics, Inc. (NASDAQ: KROS) is managing a key leadership shift as its Chief Financial Officer, Keith Regnante, departs effective early August 2026. The exit coincides with a period of heightened market pressure, during which the company’s share price has trended downward. Annita Tanini, …
Medpace Holdings, Inc. (NASDAQ: MEDP) has reported a notable second-quarter performance, with revenue climbing to $707.3 million, marking a 17.2% increase compared to $603.3 million in the same quarter last year. This growth aligns with a net earnings per share of $4.25, surpassing the …
Please wait processing your request...